Seminars in liver disease最新文献_第8页

Recent Advances in Intrahepatic Biliary Epithelial Heterogeneity. 肝内胆道上皮异质性研究进展。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2023-02-01 DOI: 10.1055/s-0042-1758833

Ashleigh Little, Abigail Medford, April O'Brien, Jonathan Childs, Sharon Pan, Jolaine Machado, Sanjukta Chakraborty, Shannon Glaser

引用次数: 1

Update on Hepatobiliary Plasticity. 肝胆可塑性的最新进展。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2023-02-01 Epub Date: 2023-02-10 DOI: 10.1055/s-0042-1760306

Minwook Kim, Fatima Rizvi, Donghun Shin, Valerie Gouon-Evans

引用次数: 0

Cirrhosis Management in the Intensive Care Unit. 重症监护病房的肝硬化管理。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2023-02-01 DOI: 10.1055/a-2015-1290

Thomas N Smith, Alice Gallo de Moraes, Douglas A Simonetto

引用次数: 1

Therapeutic Pipeline in Alcohol-Associated Liver Disease. 酒精相关肝病的治疗方案。

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2023-02-01 Epub Date: 2022-12-26 DOI: 10.1055/s-0042-1759614

Nimish Thakral, Sasha Deutsch-Link, Ashwani K Singal

{"title":"Therapeutic Pipeline in Alcohol-Associated Liver Disease.","authors":"Nimish Thakral, Sasha Deutsch-Link, Ashwani K Singal","doi":"10.1055/s-0042-1759614","DOIUrl":"10.1055/s-0042-1759614","url":null,"abstract":"Alcohol-associated liver disease is a leading cause of mortality and morbidity worldwide. Patients with alcohol-associated liver disease are often diagnosed at advanced stage and disease spectrum including alcoholic hepatitis, a severe manifestation with a high short-term mortality. Corticosteroid, recommended first-line treatment for patients with alcoholic hepatitis, is a very suboptimal treatment. Although the use of early liver transplantation has increased with consistent benefit in select patients with alcoholic hepatitis, its use remains heterogeneous worldwide due to lack of uniform selection criteria. Over the last decade, several therapeutic targets have evolved of promise with ongoing clinical trials in patients with cirrhosis and alcoholic hepatitis. Even with availability of effective medical therapies for alcohol-associated liver disease, long-term outcome depends on abstinence from alcohol use in any spectrum of alcohol-associated liver disease. However, alcohol use disorder treatment remains underutilized due to several barriers even in patients with advanced disease. There is an urgent unmet need to implement and promote integrated multidisciplinary care model with hepatologists and addiction experts to provide comprehensive management for these patients. In this review, we will discuss newer therapies targeting liver disease and therapies targeting alcohol use disorder in patients with alcohol-associated liver disease.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"43 1","pages":"60-76"},"PeriodicalIF":4.3,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11503467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9515995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging Links between Nonalcoholic Fatty Liver Disease and Neurodegeneration. 非酒精性脂肪性肝病与神经变性之间的新联系

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2023-02-01 DOI: 10.1055/s-0043-1762585

Taylor J Kelty, Ryan J Dashek, W David Arnold, R Scott Rector

{"title":"Emerging Links between Nonalcoholic Fatty Liver Disease and Neurodegeneration.","authors":"Taylor J Kelty, Ryan J Dashek, W David Arnold, R Scott Rector","doi":"10.1055/s-0043-1762585","DOIUrl":"https://doi.org/10.1055/s-0043-1762585","url":null,"abstract":"The association between liver and brain health has gained attention as biomarkers of liver function have been revealed to predict neurodegeneration. The liver is a central regulator in metabolic homeostasis. However, in nonalcoholic fatty liver disease (NAFLD), homeostasis is disrupted which can result in extrahepatic organ pathologies. Emerging literature provides insight into the mechanisms behind the liver-brain health axis. These include the increased production of liver-derived factors that promote insulin resistance and loss of neuroprotective factors under conditions of NAFLD that increase insulin resistance in the central nervous system. In addition, elevated proinflammatory cytokines linked to NAFLD negatively impact the blood-brain barrier and increase neuroinflammation. Furthermore, exacerbated dyslipidemia associated with NAFLD and hepatic dysfunction can promote altered brain bioenergetics and oxidative stress. In this review, we summarize the current knowledge of the crosstalk between liver and brain as it relates to the pathophysiology between NAFLD and neurodegeneration, with an emphasis on Alzheimer's disease. We also highlight knowledge gaps and future areas for investigation to strengthen the potential link between NAFLD and neurodegeneration.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"43 1","pages":"77-88"},"PeriodicalIF":4.2,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9157536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Endoscopic Bariatric Therapies for the Management of Nonalcoholic Steatohepatitis. 治疗非酒精性脂肪性肝炎的新型内镜减重疗法

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2022-11-01 DOI: 10.1055/a-1946-6285

Khushboo Gala, Farah Abdul Razzak, Babusai Rapaka, Barham K Abu Dayyeh

引用次数: 0

Regulation of Progression and Resolution of Liver Fibrosis by Immune Cells. 免疫细胞对肝纤维化进展和消退的调控。

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2022-11-01 DOI: 10.1055/a-1957-6384

Yuzo Koda, Nobuhiro Nakamoto, Takanori Kanai

{"title":"Regulation of Progression and Resolution of Liver Fibrosis by Immune Cells.","authors":"Yuzo Koda, Nobuhiro Nakamoto, Takanori Kanai","doi":"10.1055/a-1957-6384","DOIUrl":"https://doi.org/10.1055/a-1957-6384","url":null,"abstract":"The excessive accumulation of extracellular matrix proteins results in fibrosis-a condition implicated in several diseased conditions, such as nonalcoholic steatohepatitis, viral hepatitis, and autoimmune hepatitis. Despite its prevalence, direct and effective treatments for fibrosis are lacking, warranting the development of better therapeutic strategies. Accumulating evidence has shown that liver fibrosis-a condition previously considered irreversible-is reversible in specific conditions. Immune cells residing in or infiltrating the liver (e.g., macrophages) are crucial in the pathogenesis of fibrosis. Given this background, the roles and action mechanisms of various immune cells and their subsets in the progression and recovery of liver fibrosis, particularly concerning nonalcoholic steatohepatitis, are discussed in this review. Furthermore, the development of better therapeutic strategies based on stage-specific properties and using advanced techniques as well as the mechanisms underlying recovery are elaborated. In conclusion, we consider the review comprehensively provides the present achievements and future possibilities revolving around fibrosis treatment.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"42 4","pages":"475-488"},"PeriodicalIF":4.2,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10397704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Dietary Recommendations for the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Nutritional Geometry Perspective. 非酒精性脂肪性肝病(NAFLD)管理的饮食建议:营养几何视角

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2022-11-01 DOI: 10.1055/s-0042-1757711

Manuel Romero-Gómez, Rocío Aller, Franz Martín-Bermudo

{"title":"Dietary Recommendations for the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Nutritional Geometry Perspective.","authors":"Manuel Romero-Gómez, Rocío Aller, Franz Martín-Bermudo","doi":"10.1055/s-0042-1757711","DOIUrl":"https://doi.org/10.1055/s-0042-1757711","url":null,"abstract":"Diet could be both culprit and solution of NAFLD. Dietary modifications have been associated with histological features improvement in NAFLD. The Western diet was related to a greater risk of disease progression while the Mediterranean diet (MD) could promote regression of histological lesions. Modifications in the nutrient composition seems to have lesser impact on NAFLD than dietary modifications. An intrinsic interaction between nutrients in the diet support a specific effect not seen when added separately. Dietary modifications should focus on promoting weight loss but also look for patterns that are able to promote histological improvement. Although several micronutrients' deficit has been related to NAFLD progression, prescribing these micronutrients' supplementation did not reach a positive impact. However, an enriching diet with specific nutrients could be useful, like olive oil supplemented in MD. Geometry of nutrition defines a framework to better understand the interaction between nutrients, foods, and dietetic pattern in the model of diseases and how we could approach taking into consideration the interaction between meals and disease features. After analyzing baseline diet and histological lesions, we could calculate the distance to optimal diet and to promote changes in lifestyle to reach all these goals. A standard MD menu would be recommended.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"42 4","pages":"434-445"},"PeriodicalIF":4.2,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10329296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity? NAFLD在心血管疾病中的作用还是共病?

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2022-11-01 DOI: 10.1055/s-0042-1757712

Bing Chen, W H Wilson Tang, Mario Rodriguez, Kathleen E Corey, Arun J Sanyal, Patrick S Kamath, Biykem Bozkurt, Hafeez Ul Hassan Virk, Gregg S Pressman, Jeffrey V Lazarus, Hashem B El-Serag, Chayakrit Krittanawong

{"title":"NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?","authors":"Bing Chen, W H Wilson Tang, Mario Rodriguez, Kathleen E Corey, Arun J Sanyal, Patrick S Kamath, Biykem Bozkurt, Hafeez Ul Hassan Virk, Gregg S Pressman, Jeffrey V Lazarus, Hashem B El-Serag, Chayakrit Krittanawong","doi":"10.1055/s-0042-1757712","DOIUrl":"https://doi.org/10.1055/s-0042-1757712","url":null,"abstract":"Nonalcoholic fatty liver disease (NAFLD) and cardiovascular diseases are both highly prevalent conditions around the world, and emerging data have shown an association between them. This review found several longitudinal and cross-sectional studies showing that NAFLD was associated with coronary artery disease, cardiac remodeling, aortic valve remodeling, mitral annulus valve calcifications, diabetic cardiomyopathy, diastolic cardiac dysfunction, arrhythmias, and stroke. Although the specific underlying mechanisms are not clear, many hypotheses have been suggested, including that metabolic syndrome might act as an upstream metabolic defect, leading to end-organ manifestations in both the heart and liver. Management of NAFLD includes weight loss through lifestyle interventions or bariatric surgery, and pharmacological interventions, often targeting comorbidities. Although there are no Food and Drug Administration-approved nonalcoholic steatohepatitis-specific therapies, several drug candidates have demonstrated effect in the improvement in fibrosis or nonalcoholic steatohepatitis resolution. Further studies are needed to assess the effect of those interventions on cardiovascular outcomes, the major cause of mortality in patients with NAFLD. In conclusion, a more comprehensive, multidisciplinary approach to diagnosis and management of patients with NAFLD and cardiovascular diseases is needed to optimize clinical outcomes.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"42 4","pages":"465-474"},"PeriodicalIF":4.2,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10703423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Hepatocellular Carcinoma Chemoprevention with Generic Agents. 使用非专利药物预防肝细胞癌的发生

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2022-11-01 Epub Date: 2022-09-14 DOI: 10.1055/a-1942-6693

Fahmida Rasha, Subhojit Paul, Tracey G Simon, Yujin Hoshida

{"title":"Hepatocellular Carcinoma Chemoprevention with Generic Agents.","authors":"Fahmida Rasha, Subhojit Paul, Tracey G Simon, Yujin Hoshida","doi":"10.1055/a-1942-6693","DOIUrl":"10.1055/a-1942-6693","url":null,"abstract":"Liver cancer, mainly hepatocellular carcinoma (HCC), remains a major cause of cancer-related death worldwide. With the global epidemic of obesity, the major HCC etiologies have been dynamically shifting from viral to metabolic liver diseases. This change has made HCC prevention difficult with increasingly elusive at-risk populations as rational target for preventive interventions. Besides ongoing efforts to reduce obesity and metabolic disorders, chemoprevention in patients who already have metabolic liver diseases may have a significant impact on the poor HCC prognosis. Hepatitis B- and hepatitis C-related HCC incidences have been substantially reduced by the new antivirals, but HCC risk can persist over a decade even after successful viral treatment, highlighting the need for HCC-preventive measures also in these patients. Experimental and retrospective studies have suggested potential utility of generic agents such as lipophilic statins and aspirin for HCC chemoprevention given their well-characterized safety profile, although anticipated efficacy may be modest. In this review, we overview recent clinical and translational studies of generic agents in the context of HCC chemoprevention under the contemporary HCC etiologies. We also discuss newly emerging approaches to overcome the challenges in clinical testing of the agents to facilitate their clinical translation.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"42 4","pages":"501-513"},"PeriodicalIF":4.2,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10870259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10335119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0